This video reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.
In this video, Vered Stearns, MD, of Johns Hopkins School of Medicine in Baltimore, Maryland, reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.
Stearns gave a presentation on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy
April 28th 2024Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.